Anglo-Swedish drugmaker AstraZeneca (AZN.L) has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci (ABSI.O) to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody...
It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to...
Briacell Therapeutics Corp has been trending higher on news - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) #briacell #cancer #richtv #richtvlive #breastcancer (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is presenting positive clinical data from its lead product...
If you haven`t bought the dip: then you should know that today BCTX BriaCell Announced 10% Buyback of its Common Shares and up to 10% of Listed Warrants! My short term Price Target is 9.30usd.
There is a high probability that it can hit 250 in next 3 months, it must break above 170 first. Some big news around 170 can make it hit 250.
The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest...
BNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not...
$BCTX - BriaCell is a cancer treatment biotech that recently dropped 40% AFTER receiving fast track designation for FDA approval. The drop was somewhat coincidental as it's month long bull run finished with a FinTwit pump and dump. BUT the retrace is in and it's approaching historical trend lines and levels of support and looks poised to bounce in the coming week....
GOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer. GeoVax Labs will report Q1 2022 financial results on April 27. Jason McCarthy from Maxim Group has a $10.00 price target for GOVX. The stock is now $1.01. Market Cap of only 7.23Mil. This is a 4X upside potential short term stock in my opinion.
CWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now. On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it. 52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00. Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment. buying long term calls could be a strategy for this one. volatility is...
An "error" in previously released results sent Galera Therapeutics, Inc. (GRTX) stock price down by more than 70% in October. Today GRTX was upgraded today by HC Wainwright to buy, 10usd price target and by BTIG Research to 15usd price target. Have you bought it yesterday?
ZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
My kid came by and when i was looking at the chart, she said: hey look! a bird! and at the time, there was no bird there was only a small cone I drew for the pennant at the tip of the retracement. I zoom out a little, and noticed, wow you are right the bouncing kind of looks like ahead when you add an eye when I zoomed out more, the chart had a real recollection...
Disclaimer I am long $CVM to the tune of X0,000 shares (and growing). I genuinely believe, as a scientist, biochemist, and analyst, in Cel-Sci Corporation's Multikine. This article serves as the thesis that $CVM deserves that I have given to other stocks. As always buy shares, options are dangerous and are often used to manipulate the stock. Now that we have...
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support. The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data...
BYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy. BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China. On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving...
Disclaimer General disclaimer here. Short but sweet, we have sustained breakout from the bear pennant, we have a dwindling short pool (460k as of today borrowable from Fidelity, down from ~600k on Monday). Less kick in the shorts, and they have until the 20th of this month to sustain the price channel and try to get it under 7.5. Meanwhile, more and more...